Business Wire

Payment Solution Disruptor xpate Expands Developer Team Amid Surge in Cross-border Ecommerce

10.5.2022 13:13:00 EEST | Business Wire | Press release

Share

xpate, the rapidly-growing simplified cross-border payment solution provider, has announced a significant expansion of its disruptive developer team, with 35 new team members onboard to speed up building services aimed to enhance flexibility and data processing for merchants and acquirers.

The new appointments, with extensive experience at leading ecommerce platforms AliExpress, and enterprise cloud infrastructure builder Mirantis, will bring unrivalled levels of technical agility and creative user-focused design strengths to xpate.

The company’s ambitious growth plans, focused on helping customers to optimise payment flows and lower operational risk, have come to fruition over the last 12 months for the scaling company. The latest wave of developer hires takes xpate’s headcount to 135, from just three employees at the firm’s inception in 2018.

xpate’s momentum has been fuelled by the launch of breakthrough services such as its acquiring platform Links, and its Core Banking Solution (CBS) which speeds up and streamlines integration with various acquiring systems to give clients access to real-time data processing.

Supporting these services is xpate’s development of its own data warehouse, allowing the company to collect and store data in a centralised location to generate more deep analytics and reporting power for clients. Among the elevated service capabilities is the ability to offer businesses automatic reconciliation of third-party transactions, an internal monitoring and incident reporting system, and a customisable payment page for xpate’s merchants.

Mihails “Mike” Safro, CEO of xpate, comments: “The past three years have been something of a whirlwind, in terms of both the success of our product offerings and the growth of our team – specifically developers.

“Since xpate’s inception, we have worked tirelessly to build a company that combines technical ingenuity with a simplified user experience, to empower merchants to capitalise on all the opportunities in cross-border ecommerce. Our people are at the heart of our culture, and as such, we have assembled a diverse team of talented individuals who not only understand the importance of this ethos, but also offer unparalleled expertise and experience across the financial sector.

“While xpate has witnessed an incredible start to the business, we will certainly not be resting on our laurels. We are constantly working on improving our products and services, and look forward to sharing these exciting and ambitious developments with our customers throughout 2022 and beyond.”

These latest additions to the company’s team follow xpate achieving Mastercard principal member status in 2021 – a significant strategic partnership that has allowed xpate to enhance its platform, offer innovative solutions to new clients, bolster its merchant acquiring portfolio, and take advantage of an extended range of products and services to strengthen market offering.

For more information on xpate, go to: www.xpate.com.

###

About xpate

xpate is the payments platform that prioritises simplicity, speed and user experience.

We provide businesses with a single multi-fit solution that unites all of the desired payment methods to cover an extensive range of demands that otherwise require onboarding and integration with multiple partners.

#ENDS#

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press enquiries:
Jenna Walker
SkyParlour
jenna@skyparlour.com
07591 382 856

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye